More About Office of Technology Development Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

The Ef-Luc Mouse: An In Vivo Bioluminescent Model for the Sensitive and Noninvasive Monitoring of Tumor Growth

SK1040

Summary of Invention

The Ef-Luc mouse is a transgenic mouse model expressing luciferase driven by an E2F1 responsive promoter used for the sensitive, non-invasive, in vivo detection of tumor growth. Tumor formation as well as efficacy of anticancer treatment can be monitored over time using a single Ef-Luc Mouse.

The target market for the Ef-Luc mouse is preclinical CROs, biotech and pharma research and development operations, and academic researchers.

Background

E2F1 is a transcription factor whose activity is repressed by the retinoblastoma protein (Rb), a master regulator of cell-cycle progression through the G1 to S transition. A common feature in many distinct types of human malignancies is the loss of Rb function, resulting in upregulation of E2F1 transcriptional activity and dysregulation of cell-cycle control. Therefore, the Ef-Luc mouse can be considered a general reporter animal useful for the detection and imaging of multiple different tumor types.

The Ef-Luc mouse is an ideal tool for monitoring cell-cycle activity during tumor development in a living animal using bioluminescence imaging. Areas of abnormally high cell proliferation in the Ef-Luc mouse, namely cancerous cells, drive expression of luciferase. The resulting luciferase can be detected by injection of the Ef-Luc mouse with the luciferase substrate luciferin; luciferase oxidization of luciferin produces light that is then detected through the body of the mouse and is proportional to tumor cell burden.

Advantages

  • High sensitivity allows detection of small subcutaneous tumors (<1,000 cancer cells) and deeper lesions (1-3 cm deep), which can be undetectable by standard measurement methods.
  • Universal tumor detection increases the applicability of the Ef-Luc mouse model to multiple tumor types.
  • Quantitative measurement of tumor burden reveals subtle changes in tumor growth.
  • Rapid real-time imaging allows spatial and temporal resolution of tumor growth.
  • This noninvasive method with minimal toxicity allows repeated imaging of a single animal.
  • Fewer mice are needed per study, which reduces the cost of animal studies.

Areas of Application

  • Efficacy evaluation of anticancer treatments and therapies
  • Assessment of carcinogenic potential of compounds and environmental insults
  • Development of novel bioluminescent models of known cancer mouse models by cross-breeding
  • Evaluation of metastatic potential of primary tumors
  • Investigation of molecular mechanisms critical for tumor maintenance

References

Uhrbom L, et al. (2004) Nature Medicine. Nov; 10(11):1257-1260.

Lead Inventor

Eric C. Holland, MD, PhD

Patent Information

U.S. patent issued: 7, 041, 869

Contact Information

Alexandra Buga, MBA
Business Development Analyst
Tel: 646-888-1078

Stage of Development

Ready to use

Indications